OPEN

Inhaled Corticosteroids Use Is Not Associated With an Increased Risk of Pregnancy-Induced Hypertension and Gestational Diabetes Mellitus

Two Nested Case-Control Studies

Chang-Hoon Lee, MD, Jimin Kim, MPh, Eun Jin Jang, PhD, Joon-Ho Lee, Yun Jung Kim, MPh, Seongmi Choi, PhD, Deog Kyeom Kim, MD, PhD, Jae-Joon Yim, MD, and Ho Il Yoon, MD, PhD

Abstract: There have been concerns that systemic corticosteroid use is associated with pregnancy-induced hypertension (PIH) and diabetes mellitus. However, the relationship between inhaled corticosteroids (ICSs) and the risk of PIH has not been fully examined, and there was no study investigating the association between ICS use and the development of gestational diabetes mellitus (GDM). The aims of the study are to determine whether the use of ICSs during pregnancy increases the risk of PIH and GDM in women.

We conducted 2 nested case-control studies utilizing the nationwide insurance claims database of the Health Insurance Review and Assessment Service (Seoul, Republic of Korea), in which 1,306,281 pregnant women who delivered between January 1, 2009 and December 31, 2011 were included. Among them, PIH cases and GDM cases were identified and matched controls were included. Conditional logistic regression analyses adjusted by other concomitant drugs use during and before pregnancy and confounding covariates including comorbidities were performed.

Total 43,908 PIH cases and 219,534 controls, and 34,190 GDM cases and 170,934 control subjects were identified. When other concomitant drugs use during pregnancy was adjusted, ICS use was associated with an increased rate of PIH (adjusted odds ratio, 1.40 [95% CI, 1.05–1.87]). ICS medication possession ratios and cumulative doses were associated with an increased risk of PIH. However, the statistical significance was not found in other models. In both unadjusted and adjusted multivariable models, ICSs use was not associated with increase in the risk of GDM.

ICSs use is not associated with an increased risk of PIH and GDM.

(Medicine 95(22):e3627)

Abbreviations: DM = diabetes mellitus, DPP-4 = dipeptidyl peptidase-4, GDM = gestational diabetes mellitus, GLP-1 = glucagon-like peptide-1, HIRA = Health Insurance Review and Assessment Service, ICD-10 = International Statistical Classification of Diseases and Related Health Problems, 10th edition, ICSs = inhaled corticosteroids, LABAs = long-acting inhaled β 2-agonists, LAMAs = long-acting inhaled muscarinic antagonists, LTRAs = leukotriene receptor antagonists, MPRs = medication possession ratios, NHI = National Health Insurance, PCOS = polycystic ovary syndrome, PIH = pregnancy-induced hypertension, SABAs = short-acting inhaled β 2-agonists.

INTRODUCTION

rug safety is an important issue during pregnancy. Corticosteroid is one of the drugs that require a special caution for pregnant women to use. There have been concerns that systemic corticosteroid use is associated with worsened pregnancy outcomes including pregnancy-induced hypertension (PIH).^{1,2} Hypertension disorders occur in 6% to 8% of pregnancies and contribute significantly to perinatal morbidity and mortality.^{2,3} The causes of most PIH cases, however, remain unknown.^{2,3} Systemic administration of glucocorticoids increases insulin resistance by reducing glucose transport 4 expression levels and attenuating cell migration,⁴ and decreases glycogen synthetase levels,^{5–8} which leads to glucose intoler-ance and type 2 diabetes mellitus (DM).^{9–11} Gestational DM (GDM) is a significant medical problem during pregnancy.^{12–15} GDM shares not only characteristics with type 2 DM such as insulin resistance but also risk factors, and the majority of women with GDM eventually develop DM after pregnancy.16 There are concerns that the use of systemic corticosteroids is associated with GDM.1

Inhaled corticosteroids (ICSs) are delivered to the airways and lungs through respiratory devices. Delivering corticosteroids through inhalation devices is generally thought to be safe in terms of systemic side effects. However, some of the drugs can reach the pulmonary parenchymal tissue and enter the systemic circulation.¹⁸ In fact, studies have reported that long-term use of ICSs may result in adrenal suppression and possibly adrenal crisis when stopped.^{19,20}

Editor: Daryle Wane.

Received: February 5, 2016; revised and accepted: April 8, 2016.

From the National Evidence-Based Healthcare Collaborating Agency (C-HL, JK, EJJ, YJK, SC, DKK, J-JY, HIY); Division of Pulmonary and Critical Care Medicine (C-HL, J-JY), Department of Internal Medicine, Seoul National University College of Medicine; Department of Obstetrics and Gynecology (J-HL), Seoul National University College of Medicine, Seoul National University Hospital; Division of Pulmonary and Critical Care Medicine (DKK), Department of Internal Medicine, Seoul Mational University Boramae Medical Center; Division of Pulmonary and Critical Care Medicine, Seoul National University Boramae Medical Center; Division of Pulmonary and Critical Care Medicine, Seoul Mational University College of Medicine, Seoul National University Boramae Medical Center; Division of Pulmonary and Critical Care Medicine (HIY), Department of Internal Medicine, Seoul National University Boramae Medical Center; Division of Pulmonary and Critical Care Medicine (HIY), Department of Internal Medicine, Seoul National University Boramae Medical Center; Division of Pulmonary and Critical Care Medicine (HIY), Department of Internal Medicine, Seoul National University Boramae Medical Center; Division of Pulmonary and Critical Care Medicine (HIY), Department of Internal Medicine, Seoul National University Boramae Medical Center; Division of Pulmonary and Critical Care Medicine (HIY), Department of Internal Medicine, Seoul National University Boramae Medical Center; Division of Pulmonary and Critical Care Medicine (HIY), Department of Internal Medicine, Seoul National University Boramae Medical Center; Division of Pulmonary and Critical Care Medicine (HIY), Department of Internal Medicine, Seoul National University Boramae Medical Center; Seoul National University Boramae Medical Center; Division of Pulmonary and Critical Care Medicine (HIY), Department of Health Policy and Hospital Management, Graduate School of Public Health, Korea University (JK).

Correspondence: Ho Il Yoon, Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam-Si, Republic of Korea (e-mail: dextro70@gmail.com).

All authors participated in study design, data analysis, and interpretation of the data. All authors were involved in writing and revising the manuscript, and agreed the submission of the paper.

C-HL and JK are co-first authors who equally contributed to this study.

This study was supported by the National Evidence-Based Healthcare Collaborating Agency (NA13-004).

The authors have no conflicts of interest to disclose.

Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

ISSN: 0025-7974

DOI: 10.1097/MD.00000000003627

For the reasons, there have been concerns that ICS use may be related to PIH development because systemic corticosteroids are associated with PIH.^{1,2} However, there have been only a few studies investigating the relationship between ICS use and the risk of PIH.^{1,2,21,22} In addition, these studies have several limitations, including small numbers of cases with PIH²² or only including women with asthma which is a risk factor of PIH,²³ which could attenuate the effect of ICSs on PIH. ICSs can be used for other purposes, including as a trial for postinfectious cough²⁴ and treatment of nonasthmatic eosinophilic bronchitis.²⁵ There were several studies reporting that systemic corticosteroid administration in pregnant women at risk of impending preterm delivery to enhance fetal lung maturation increased maternal serum glucose levels,^{26,27} and that the use of systemic corticosteroids is associated with GDM.¹⁷ However, there were few studies that investigated the association between ICS use and GDM.

The purpose of this study was to determine whether or not the use of ICS during pregnancy would increase the risk of PIH and GDM in women with or without asthma through 2 nested case-control studies utilizing a nationwide database.

METHODS

Data Source

We analyzed the database of the Health Insurance Review and Assessment Service (HIRA; Seoul, Republic of Korea), a government agency examining the accuracy of claims for National Health Insurance (NHI) and National Medical Aid in Korea. NHI covers 96.6% of 48.6 million Koreans²⁸ and the reliability and high quality of the HIRA database is highlighted by the large number of articles that have utilized the data.^{28–32} HIRA database includes demographic variables and all medical services rendered, along with diagnostic codes (International Statistical Classification of Diseases and Related Health Problems, 10th edition, ICD-10) and all prescribed medications. The protocol of this study was approved by the Institute of review Board of the National Evidence-Based Healthcare Collaborating Agency, Seoul, Republic of Korea. Written consent for participants was waived because the study had a retrospective design.

Subject

The cohort included 1,306,281 pregnant women who delivered between January 1, 2009, and December 31, 2011.

We performed 2 nested case-control studies using this cohort. For the first study examining the effects of ICS on PIH, we excluded 13,633 women who were prescribed anti-hypertensive drugs for 30 days or longer periods either within 1 year prior to pregnancy or 4 to 12 months after delivery from analysis.² Antihypertensive drugs included β -blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, diuretics, and calcium-channel blockers. Thus, 1,293,648 pregnant women who had no history of hypertension were included in the first case-control study. We defined 43,908 pregnancy-induced hypertension cases and 219,534 matched controls from this cohort.

For the second phase of analysis determining the effects of ICS on GDM, we excluded 37,349 women who were either diagnosed with DM (ICD-10 code E10-14) or prescribed any anti-DM drugs for 30 days or longer either within 1 year before pregnancy or within 1 year after delivery. Anti-DM drugs included sulfonylurea, metformin, meglitinide, α -glucosidase inhibitors, thiazolidinediones, dipeptidyl peptidase-4(DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) analogues, and insulin. Thus, 1,268,932 pregnant women who had no history of DM were included in the second phase of the analysis. We defined 34,190 GDM cases and 170,934 matched controls (to a ratio of 1:5) from this cohort (Figure 1).

Definition of Cases and Controls

We defined PIH cases as those with ICD-10 code O11– O15 during pregnancy. Controls without PIH were randomly assigned (up to 1:5) matching age (\pm 5 years), baby birth date,




FIGURE 1. Flowchart of patient selection.

ICS use before pregnancy, presence of DM, and presence of asthma during or within 1 year before pregnancy. We defined GDM cases as those with ICD-10 code O24.4 during pregnancy. Controls without GDM matching age (\pm 5 years), baby birth date, ICS use before pregnancy, and/or asthma during or within 1 year before pregnancy were randomly selected up to 5 times of GDM cases. The index date was defined as the date of first assignment of the ICD-10 code. The index date for the controls was defined as the index date for their matching cases.

Exposure to Respiratory Medications Including Inhaled Drugs

Respiratory drugs included ICSs (beclomethasone, budesonide, triamcinolone, ciclesonide, fluticasone, or flunisolide), short-acting inhaled B2-agonists (SABAs; salbutamol, fenoterol, procaterol, or terbutaline), long-acting inhaled B2-agonists (LABAs; salmeterol or formoterol), long-acting inhaled muscarinic antagonists (LAMAs; tiotropium), a combination of ICS and LABA (fluticasone/salmeterol or budesonide/formoterol), systemic corticosteroids (hydrocortisone, cortisone, prednisone, prednisolone, methylprednisolone, triamcinolone, betamethasone, or dexamethasone), and leukotriene receptor antagonists (LTRAs; montelukast, pranlukast, or zafirlukast). Respiratory drug use was defined as a prescription for 30 days or longer period. ICS cumulative doses were calculated as the sum of the prescribed doses converted as fluticasone equivalents. The equivalent doses for inhaled corticosteroids were 100 µg beclomethasone, 50 µg beclomethasone, 80 µg budesonide, $200 \,\mu g$ triamcinolone, $32 \,\mu g$ ciclesonide, $50 \,\mu g$ fluticasone, and $200 \,\mu g$ flunisolide.^{28,30,33} ICS medication possession ratios (MPRs) were calculated as the total days of prescription for inhaled corticosteroids divided by the 180 days.

Covariates

To investigate the association between ICSs and the development of PIH or GDM, we adjusted age, each disease-associated comorbidity, other concomitant respiratory medication uses during and before pregnancy and healthcare utilization. PIH-associated comorbidities included PIH in the prior pregnancy, chronic kidney disease (ICD-10 code N18 or undergoing dialysis), antiphospholipid antibody syndrome or inherited thrombophilia (ICD-10 code D68.5 or D68.6), vascular or connective tissue diseases (ICD-10 code M05-60 or M32), hydrops fetalis (ICD-10 code P56, P83.2, or O36.2), unexplained fetal growth restriction (ICD-10 code P05-08), hydatidiform mole (ICD-10 code Z35.1, D39.2, or O01 or procedure for hydatidiform mole), and multiple gestation. GDM-associated comorbidities were preeclampsia in the prior pregnancy, prior history of pregnancy, history of GDM(O24) during a previous pregnancy, history of pregnancy-induced hypertension (O11-O15) during a previous pregnancy, history of impaired glucose metabolism (R73), history of hypertension (I10-I15), history of antihypertensive drug use, history of dyslipidemi (E780, 786, 789), and history of polycystic ovary syndrome (PCOS). Concomitant medication use included LTRAs, systemic corticosteroids, and SABAs used during (within 180 days prior to the index date) and before pregnancy (within 180 days prior to pregnancy). Healthcare utilization included visits to obstetricians and visits to pulmonologists during pregnancy.

Statistical Methods

To describe the baseline characteristics of cases and controls, statistics including proportions, medians, and interquartile ranges were used. We also summarized continuous variables into the appropriate categorical variables based on their distributions. Statistical significances were derived from independent t tests for continuous variables and X^2 tests for categorical variables. To investigate the association between ICSs and the development of PIH and GDM, conditional logistic regression analyses were performed. Confounding covariates that showed statistically significant differences between cases and controls and the use of respiratory medications were also included in the multivariable models. Likelihood ratio tests were used to examine the goodness of fit of the model, and no significant lack of fit was found. To explore the dose-response relationship, we initially divided the distribution of the cumulative inhaled corticosteroid dose into $<15,000 \,\mu g$ or $\ge 15,000 \,\mu g$. Adjusted odds ratios (aOR) were presented with 95% confidence intervals (CI) and P values. A P value of less than 0.05 was regarded as statistically significant, and all statistical analyses were performed using SAS, version 9.2 (SAS Institute, Cary, NC).

RESULTS

Effects of ICSs on PIH

Table 1 shows the characteristics of cases and controls. Table 2 shows the respiratory medications used by cases and controls. Eighty-seven pregnant women were prescribed respiratory drugs. PIH patients exhibited higher ICS MPRs, higher ICS cumulative dose during pregnancy, and higher ICS cumulative dose within 6 months before pregnancy compared with controls. ICS use within 180 days before the index date was significantly associated with increased odds of PIH (model 1: aOR, 1.33% [CI, 1.02–1.72]) after adjustment for other concomitant respiratory medication during pregnancy (Table 3). The statistical significance was no longer present in the analysis adjusting for other concomitant respiratory medication use during pregnancy, age, associated comorbidities, healthcare utilization, and respiratory medication use before pregnancy (model 3). ICS MPRs >0.3 and ICS cumulative doses over 15,000 µg were also significantly associated with an increased risk of PIH, which remained statistically significant in model 3.

Effects of ICSs on GDM

The frequency of respiratory medications including ICSs was not different in cases and controls as shown in Table 2. The use of ICS within 180 days before the index date was not significantly associated with an increased risk of GDM, and this lack of association remained significant after adjustment for confounding covariates in different multivariable analysis models. ICS use was significantly associated with a lower risk of GDM in certain models (ICS MPR 0–0.3 vs. 0; aOR, 0.80; 95% CI, 0.61–0.95; P = 0.017 after adjustment for other concomitant respiratory medication, age, associated comorbidities, and healthcare utilization (model 2)) (Table 4).

DISCUSSION

Our nationwide nested case-control studies showed that ICS use is not associated with the risk of PIH and GDM. However, after adjustment for other concomitant respiratory medication, ICS use significantly was associated with increase in the risk of PIH, although this association was no longer significant in other multivariate models. There was also a statistically significant dose–response relationship between

$ \begin{array}{cccccccccccccccccccccccccccccccccccc$		Characteristic	PIH (N=43,908) n (%)	Control (N = 219,534) n (%)	P Value	GDM (N = 34,190) n (%)	Control (N = 170,934) n (%)	P Value
		*						
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$							
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$		30.7 ± 4.10	30.6 ± 4.14	Matched	21.9 ± 3.9	20.7 土 4.2 21、200、202	Matched
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	1edian (Q1, Q3)	30 (28, 33)	31 (28, 33)		32 (29, 34)	31 (28, 33)	
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	<20	304 (0.69%)	1770 (0.81%)		73 (0.2%)	1943(1.1%)	
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	20 - 29	16,705 (38.05%)	80,240 (36.55%)		8591 (25.1%)	63,356 (37.1%)	
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	30-39	25,802 (58.76%)	133,125 (60.64%)		24,510 (71.7%)	101,665 (59.5%)	
ialists during pregnarcy 0.0 ± 0.18 0.0 ± 0.18 0.00 ± 0.18 0.01 ± 0.2 $3.800199.19%$, $3.500199.19%$, $3.500199.00\%$, 3.500166% , 3.500166% , 3.5101066% , 3.50011 , 3.520106% , 3.51614% , 3.510106% , 3.51614% , 3.510106% , 3.51614% , 3.51617% , 3.510106% , 3.51616% , 3.51260% , 3.51616% , 3.51616% , 3.51616% , 3.51616% , 3.51616% , 3.5126% , 3.51616% , 3.51616% , 3.51616% , 3.51616% , 3.51616% , 3.51616% , 3.51616% , 3.51616% , 3.51616% , 3.51616% , 3.51616% , 3.51616% , 3.51616% , 3.51616% , 3.51616% , 3.51616% , 3.51616% , 3.516% , 3.51616% , 3.51616% , $3.516000000000000000000000000000000000000$	ialists during pregnarcy 0.140 , $0.04.018$, 0.101 , 0.01 ± 0.2 , 0.011 , 0.01 ± 0.2 , 0.001 , 0.029% , 0.001 , 0.029% , 0.001 , 0.029% , 0.001 , 0.001 , 0.001 , 0.001 , 0.001 , 0.001 , 0.001 , 0.001 , 0.001 , 0.001 , 0.001 , 0.001 , 0.002 , 0.001 , 0.002 , 0.001 , 0.002 , 0.001 , 0.002 , 0.001 , 0.002 ,	40	(0%05.2) / 601	4399 (2.00%)		1016 (3.0%)	39/0 (2.3%)	
adding pregnarroy 00 ± 0.1 0.0 ± 0.21 0.0 ± 0.21 0.0 ± 0.21 0.0 ± 0.21 0.0 ± 0.01 0.0 ± 0.001 0.0 ± 0.0001 0.0 ± 0.0001 0.	addring pregnatively $\begin{array}{cccccccccccccccccccccccccccccccccccc$	lealth care utilization						
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	isits to respiratory specialists during pi						
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Mean (SD)	0.0 ± 0.21	0.0 ± 0.18	0.101	0.01 ± 0.2	0.02 ± 0.2	0.076
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	0	43,507 (99.09%)	217,641 (99.14%)	0.580	33,891 (99.1%)	169,355 (99.1%)	0.246
$ \begin{array}{c cccccccc} & 110 \ (0.2\%) & 519 \ (0.2\%) & 519 \ (0.2\%) & 519 \ (0.2\%) & 519 \ (0.2\%) & 519 \ (0.2\%) & 519 \ (0.2\%) & 519 \ (0.2\%) & 519 \ (0.2\%) & 519 \ (0.2\%) & 519 \ (0.2\%) & 519 \ (0.2\%) & 519 \ (0.2\%) & 519 \ (0.2\%) & 519 \ (0.2\%) & 510 \ (0.2\%) & 510 \ (0.2\%) & 510 \ (0.2\%) & 510 \ (0.2\%) & 510 \ (0.2\%) & 510 \ (0.2\%) & 510 \ (0.2\%) & 510 \ (0.2\%) & 500 \ (0.2\%) & 500 \ (0.2\%) & 500 \ (0.2\%) & 500 \ (0.2\%) & 500 \ (0.2\%) & 500 \ (0.2\%) & 500 \ (0.2\%) & 500 \ (0.2\%) & 57$	$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	1	291 (0.66%)	1374 (0.63%)		225 (0.7%)	1125(0.7%)	
ialists during pregnancy 11.3 \pm 5.4.96 10.7 \pm 5.31 < 0.001 12.3 \pm 4.8 13.6 (0.12%) 10.7 \pm 5.31 < 0.001 12.3 \pm 4.8 17.6467 (0.372%) 12.28 (0.56%) 0.001 12.3 (0.44%) 0.639 (0.42%) 0.531 (0.44%) 0.639 (0.19%) 0.639 (0.19%) 0.639 (0.19%) 0.639 (0.19%) 0.639 (0.19%) 0.639 (0.19%) 0.639 (0.19%) 0.639 (0.19%) 0.67 984 (30.97%) 0.011 2.22 (0.8%) 0.575 (1.7%) 0.344 (30.97\%) 0.344 (30.97\%) 0.344 (31.67\%) 0.344 (31.67\%) 0.344 (31.67\%) 0.344 (31.67\%) 0.344 (31.67\%) 0.344 (31.67\%) 0.336 (17.65\%) 0.344 (31.67\%) 0.344 (31.23\%) 0.344 (31.67\%) 0.336 (17.65\%) 0.32\% (31.9\%) 0.344 (31.23\%) 0.336 (17.65\%) 0.32\% (30.97\%) 0.344 (31.23\%) 0.336 (17.65\%) 0.32\% (30.97\%) 0.344 (31.23\%) 0.336 (17.65\%) 0.32\% (30.97\%) 0.344 (31.23\%) 0.336 (17.65\%) 0.034 (31.67\%) 0.002 (33	ialists during pregnancy 11.3 \pm 5.4.96 10.7 \pm 5.31 < 0.001 12.3 \pm 4.8 13.6 (0.12%) 12.4.5 (0.57%) 0.12% (0.57%) 0.001 12.3 \pm 4.8 53.6 (1.9%) 0.53 (0.12%) 0.53 (0.42%) 0.501 12.5 (1.4%) 0.53 (0.42%) 0.53 (0.42%) 0.53 (0.42%) 0.53 (0.42%) 0.53 (0.42%) 0.53 (0.42%) 0.53 (0.42\%) 0.34 (0.3\%) 0.34 (0.3\%) 0.34 (0.3\%) 0.33 (0.03\%) 0.33 (0.25\%) 0.33 (0.25\%)	≥ 2		519(0.24%)		74 (0.2%)	454 (0.3%)	
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	isits to obstetrical specialists during pr	regnancy					
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	(ean (SD)	$11.3 \pm 5.4.96$	10.7 ± 5.31	< 0.001	12.3 ± 4.8	11.3 ± 5.2	< 0.001
$ \begin{array}{ccccccc} & & & & & & & & & & & & & & & &$	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	0	53 (0 12%)	1228 (0.56%)	< 0.001	32 (0 1%)	225 (0 1%)	< 0.001
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	1.0	16 167 (27 5002)	01 130 (41 5102)	100.0/	10 381 (30 402)	64 050 (37 502)	
$ \begin{array}{ccccccccc} & & & & & & & & & & & & & & &$	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	10 14		(0/10:11) CC1,17		14 156 (41 402)	(1)(2)(2)(2)(2)(2)(2)(2)(2)(2)(2)(2)(2)(2)	
$ \begin{array}{ccccccc} y & y & y & y & y & y & y & y & y & y $	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	10-14	1/, 149 (40.42.70) 0000 001 0000 001 000000000000000000	(0.70, 70, 70, 70, 70, 70, 70, 70, 70, 70,		(0/ +.1+) 0/ 1+1 0/01 /00 10/)		
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	داخ. ۲. از ۲.	(0%06.12) 6006	41,093 (21.12%)			42,197 (24.7%)	
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	TOT INSTORY OF PREGNANCY	(1020 C) 808	057 (0.440/)	100.07		015 (V 50/)	100.07
13.598 (30.97%) $67,984$ (30.97%) Matched $70.1(1.7\%)$ 10.126 5568 1168 (2.66%) 6016 (2.74%) 0.344 2184 (6.4%) 5568 3361 (7.65%) $16,802$ (7.65%) $Matched$ 3125 (9.1%) 5568 3361 (7.65%) $16,802$ (7.65%) $16,802$ (7.65%) 0.344 2184 (6.4%) 5568 y syndrome or 30 (0.23%) 256 (0.12%) 256 (0.12%) 0.001 3125 (9.1%) $15,611$ y syndrome or 14 (0.03%) 255 (0.12%) 0.002 0.002 1879 (0.86%) 0.002 x succision 89 (0.20%) 1879 (0.86%) 0.002 10072 1103 (3.2%) 4676 x is the diseases 341 (0.78%) 1879 (0.86%) 0.002 1103 (3.2%) 4676 1103 (3.2%) 4676 1103 (3.2%) 4676 1103 (3.2%) 4676 1103 (3.2%) 4676 1103 (3.2%) 14676 1103 (3.2%) 14676 1103 (3.2%) 14676 1103 (3.2%) 14676 1103 (3.2%) 14676 1103 (3.2%) <td>13.598 (30.97%) $67,984$ (30.97%) Matched 732 (1.7%) 133 1168 (2.66%) 6016 (2.74%) 0.344 2184 (6.4%) 5568 1168 (2.66%) 6016 (2.74%) 0.344 2184 (6.4%) 5568 3361 (7.65%) $16,802$ (7.65%) $16,802$ (7.65%) $Matched$ 3125 (9.1%) 5568 y syndrome or 103 (0.23%) 256 (0.12%) 0.002 3125 (9.1%) $15,611$ y syndrome or 14 (0.03%) 265 (0.12%) 0.002 3125 (9.1%) 1561 y syndrome or 14 (0.03%) 265 (0.12%) 0.002 100 (0.3%) 157 x succision 89 (0.20%) 1879 (0.86%) 0.002 1004 3276 4676 x succision 89 (0.20%) 1879 (0.86%) 0.002 1003 1276 1000 2567 (7.8%) 14676 x succision 80 (0.20%) 1387 (0.27%) 0.002 1003 1032% x succision 80 (0.20%) 1879 (0.27%) 0.002 1003 10.32%</td> <td></td> <td>(0/01.7) 060</td> <td>(0/44/0) / 66</td> <td><0.001</td> <td>212 (0.0%) 575 (1 70/)</td> <td>$(0\%C.0)$ C/δ</td> <td></td>	13.598 (30.97%) $67,984$ (30.97%) Matched 732 (1.7%) 133 1168 (2.66%) 6016 (2.74%) 0.344 2184 (6.4%) 5568 1168 (2.66%) 6016 (2.74%) 0.344 2184 (6.4%) 5568 3361 (7.65%) $16,802$ (7.65%) $16,802$ (7.65%) $Matched$ 3125 (9.1%) 5568 y syndrome or 103 (0.23%) 256 (0.12%) 0.002 3125 (9.1%) $15,611$ y syndrome or 14 (0.03%) 265 (0.12%) 0.002 3125 (9.1%) 1561 y syndrome or 14 (0.03%) 265 (0.12%) 0.002 100 (0.3%) 157 x succision 89 (0.20%) 1879 (0.86%) 0.002 1004 3276 4676 x succision 89 (0.20%) 1879 (0.86%) 0.002 1003 1276 1000 2567 (7.8%) 14676 x succision 80 (0.20%) 1387 (0.27%) 0.002 1003 1032% x succision 80 (0.20%) 1879 (0.27%) 0.002 1003 10.32%		(0/01.7) 060	(0/44/0) / 66	<0.001	212 (0.0%) 575 (1 70/)	$(0\%C.0)$ C/δ	
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$					(0/1.1) C/C	(0%6.0) 1661	<0.001
$ \begin{array}{ccccccccccc} & 1168 (2.66\%) & 6016 (2.74\%) & 0.344 & 2184 (6.4\%) & 5568 \\ 31361 (7.65\%) & 16,802 (7.65\%) & Matched & 3125 (0.9\%) & 15,611 \\ 31361 (3.65\%) & 103 (0.23\%) & Matched & 3125 (0.9\%) & 15,611 \\ 509 (0.23\%) & 209 (0.23\%) & 0.001 & 484 \\ y syndrome or & 10 (0.3\%) & 225 (0.12\%) & 0.002 & \\ y syndrome or & 14 (0.03\%) & 226 (0.19\%) & 0.002 & \\ a size diseases & 341 (0.78\%) & 1879 (0.86\%) & 0.094 & \\ a size diseases & 341 (0.78\%) & 1879 (0.86\%) & 0.002 & \\ 1 (0.02\%) & 1879 (0.06\%) & 0.003 & \\ 1 (1,02\%) & 593 (0.27\%) & 0.069 & 1103 (3.2\%) & 4676 & \\ 1 (1,022\%) & 593 (0.27\%) & 0.069 & 1103 (3.2\%) & 1103 (3.2\%) & \\ 1 (1,022\%) & 593 (0.27\%) & 0.069 & 1103 (3.2\%) & 1103 (3.2\%) & \\ 1 (1,022\%) & 1 (1,012\%) & 0.069 & 1103 (3.2\%) & 1103 (3.2\%) & \\ 1 (1,022\%) & 1 (1,0122\%) & 0.069 & 1103 (3.2\%) & 1103 (3.2\%) & 1103 (3.2\%) & \\ 1 (1,022\%) & 1 (1,0122\%) & 0.069 & 1103 (3.2\%) & 1103 (3.2\%) & 1006 & \\ 1 (1,012\%) & 1 (1,0122\%) & 0.069 & 1103 (3.2\%) & 1006 & \\ 1 (1,012\%) & 1 (1,0122\%) & 0.069 & 1103 (3.2\%) & 1006 & \\ 1 (1,012\%) & 1 (1,0122\%) & 0.069 & 1103 (3.2\%) & 1006 & \\ 1 (1,012\%) & 1 (1,0122\%) & 0.069 & 1103 (3.2\%) & 0.069 & 1103 (3.2\%) & 0.069 & 0.060$	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	DM^{s}	13,598 (30.97%)	67,984 (30.97%)	Matched			
I168 (2, 66%) 3361 (7, 65%)6016 (2, 74%) 509 (0, 23%)0.344 Matched2.104 (0, 70) 100 (0, 3%)2000 1484t prior to103 (0, 23%)16, 802 (7, 65%) 509 (0, 23%)Matched3125 (9, 1%) 100 (0, 3%)15, 611 484ty syndrome or89 (0, 20%)265 (0, 12%) 0.002 <0.001 <0.001 484issue diseases341 (0, 78%)1879 (0.86%) 0.002 <0.001 <0.002 a issue diseases341 (0, 78%)1879 (0.86%) 0.002 <0.001 <0.002 issue diseases341 (0, 78%)1879 (0.66%) <0.001 <0.002 <0.032 issue diseases341 (0, 32%)533 (0.06%) <0.001 <0.002 <0.001 issue diseases341 (0, 32%)533 (0.06%) <0.001 <0.032 <0.032 issue diseases341 (0, 32%)138 (0.06%) <0.001 <0.032 <0.032 issue diseases341 (0, 32%) <0.002 <0.001 <0.032 <0.001 issue diseases341 (0, 32%) <0.009 <0.001 <0.001 <0.001 issue diseases <0.002 <0.001 <0.003 <0.001 <0.001 issue diseases <0.002 <0.001 <0.003 <0.001 <0.003 issue diseases <0.001 <0.001 <0.001 <0.001 <0.001 issue diseases <0.001 <0.001 <0.001 <0.001 <0.001 issue disease <0.0001 <0.001 <0.001 <0.001 <	I168 (2, 66%) 3361 (7, 65%)6016 (2, 7, 4%) 509 (0, 23%)0.344 Matched2.104 (0, 7%) 100 (0, 3%)15, 611 484t prior to103 (0, 23%)16, 802 (7, 65%) 509 (0, 23%)Matched3125 (9, 1%) 100 (0, 3%)15, 611 484ty syndrome or89 (0, 20%)265 (0, 12%) 0.002 <0.001 0.002484a a issue diseases341 (0, 78%)255 (0, 12%) 0.002 <0.001 100 (0, 3%)457a b issue diseases341 (0, 78%)1879 (0.86%) 0.0020.0020.0021034676a b issue diseases341 (0, 78%)1879 (0.86%) 0.0030.0031103 (3.2%)4676a issue diseases341 (0, 32%)593 (0.27%)0.0091103 (3.2%)4676a issue141 (0, 32%)593 (0.27%)0.0091103 (3.2%)5582bism141 (0, 32%)593 (0.27%)0.0091103 (3.2%)5582drugs1103 (3.2%)579 (1.7%)5582579 (1.7%)2454drugs579 (1.7%)579 (1.7%)2454568579 (1.7%)2454etse mellitus, ICS = inhaled corticosteroids, PIH = pregnancy-induced hypertension.60 delivery date (during pregnancy).2410267 (1.7%)2454265 (1.7%)265 (1.7%)265 (1.7%)265 (1.7%)265 (1.7%)<	uting uns pregnancy				1101 16 402)	2260 13 302)	/0.001
Trian <th< td=""><td>Tricl<th< td=""><td>rin Atialo contotion</td><td>(7077 67 6711</td><td>(707 C/ 2109</td><td>0 344</td><td>2104 (0.470)</td><td>(0/5.5) 0055</td><td>100.0</td></th<></td></th<>	Tricl <th< td=""><td>rin Atialo contotion</td><td>(7077 67 6711</td><td>(707 C/ 2109</td><td>0 344</td><td>2104 (0.470)</td><td>(0/5.5) 0055</td><td>100.0</td></th<>	rin Atialo contotion	(7077 67 6711	(707 C/ 2109	0 344	2104 (0.470)	(0/5.5) 0055	100.0
prior to103 (0.23%) $100 (0.3\%)$ $100 (0.3\%)$ 144 $100 (0.3\%)$ 509 (0.23%) $100 (0.3\%)$ 484 $100 (0.3\%)$ $265 (0.12\%)$ 0.001 $100 (0.3\%)$ 484 $110 (0.3\%)$ $22 (0.01\%)$ 0.002 0.002 $110 (0.2\%)$ $127 (0.03\%)$ $1879 (0.86\%)$ 0.004 $110 (0.22\%)$ $1879 (0.86\%)$ 0.004 0.004 $110 (0.22\%)$ $1879 (0.66\%)$ 0.004 $100 (0.3\%)$ $110 (0.22\%)$ $138 (0.06\%)$ 0.004 $253 (0.27\%)$ $110 (0.32\%)$ $593 (0.27\%)$ 0.069 $1103 (3.2\%)$ $110 (0.32\%)$ $593 (0.27\%)$ 0.069 $1103 (3.2\%)$ $110 (0.32\%)$ $593 (0.27\%)$ 0.069 $1103 (3.2\%)$ $110 (0.32\%)$ $593 (0.27\%)$ $579 (1.7\%)$ $11,771$ $110 (0.32\%)$ $579 (1.7\%)$ $11,771$ $110 (0.32\%)$ $579 (1.7\%)$ $11,771$ $110 (0.32\%)$ $579 (1.7\%)$ $11,771$ $110 (0.32\%)$ $579 (1.7\%)$ $11,770$ $110 (0.32\%)$ $1000 (0.3\%)$ $200 (0.000)$ $110 (0.000)$ $1100 (0.000)$ $11,770$ $110 (0.000)$ $1100 (0.000)$ $1100 (0.000)$ $110 (0.000)$ $1100 (0.000)$ $1100 (0.000)$ $110 (0.000)$ $1000 (0.000)$ $1000 (0.000)$ $110 (0.000)$ $1000 (0.000)$ $1000 (0.000)$ $110 (0.000)$ $1000 (0.000)$ $1000 (0.000)$ $110 (0.000)$ $1000 (0.000)$ $1000 (0.000)$ $110 (0.000)$ $1000 (0.000)$ 100	prior to103 (0.23%) $100 (0.3\%)$ $100 (0.3\%)$ 144 $100 (0.3\%)$ $509 (0.23\%)$ $100 (0.3\%)$ 484 $100 (0.3\%)$ $100 (0.3\%)$ $100 (0.3\%)$ 484 $100 (0.3\%)$ $100 (0.3\%)$ 0.002 0.002 $100 (0.3\%)$ $12 (0.03\%)$ $225 (0.12\%)$ 0.002 $100 (0.3\%)$ $12 (0.03\%)$ $222 (0.01\%)$ 0.002 $100 (0.3\%)$ $12 (0.03\%)$ $222 (0.01\%)$ 0.002 $110 (0.22\%)$ $1879 (0.86\%)$ 0.004 0.002 $110 (0.22\%)$ $138 (0.06\%)$ 0.004 0.002 $110 (0.32\%)$ $593 (0.27\%)$ 0.002 $1103 (3.2\%)$ $110 (0.32\%)$ $593 (0.27\%)$ 0.069 $1103 (3.2\%)$ $110 (0.32\%)$ $593 (0.27\%)$ 0.069 $1103 (3.2\%)$ $110 (0.32\%)$ $1103 (3.2\%)$ $2675 (7.8\%)$ 11771 $110 (0.32\%)$ 10.06% $1103 (3.2\%)$ $579 (1.7\%)$ $110 (0.32\%)$ $110 (0.32\%)$ $2675 (7.8\%)$ 11771 $110 (0.32\%)$ $110 (0.32\%)$ $2675 (7.8\%)$ $2675 (7.8\%)$ $110 (0.32\%)$ 10.006 $1100 (0.3\%)$ $2675 (7.8\%)$ 11771 $110 (0.32\%)$ 10.006 $1100 (0.3\%)$ $2675 (7.8\%)$ 11771 $110 (0.32\%)$ 10.006 $1100 (0.3\%)$ $2675 (7.8\%)$ 11771 $10 (0.001 (0.$	intuple gestation	1108 (2.00/0) 3361 (7 65%)	16 807 (7.74%)	Matched	3175 (0 1%)	15 611 (0 10%)	Matchad
$ \begin{array}{ccccccccc} \begin{tabular}{ccccc} & 0.0 & 0$	$ \begin{array}{cccccccc} \label{eq:relation} & \begin{tabular}{c} tabular$	'S use within 6 months prior to	(0/00.7) 1000	(0, 00, 1) = (0, 0, 0, 0)	Matched	(0/1.6) (216)	(0/17) 110,01 484 (0 30%)	Matched
		ω use within 0 months prior w	(0/ 57:0) 501		INTRICTICCI			INTRICTION
		pregnancy (200 uays)						
ic kidney disease 89 (0.20%) 265 (0.12%) <0.001 rited thrombophilia 0.002 rited thrombophilia 14 (0.03%) 22 (0.01%) 0.004 lar or connective tissue diseases 341 (0.78%) 1879 (0.86%) 0.094 ps fetalis 8 (0.02%) 1879 (0.86%) 0.094 ps fetalis 8 (0.02%) 1879 (0.86%) 0.0094 ps fetalis 141 (0.32%) 593 (0.27%) 0.009 difform mole 0.000 difform mole 0.000 difform mole 0.000 difform mole 0.000 and on the 0.000 difform mole 0.000 difform mol	ic kidney disease 89 (0.20%) 265 (0.12%) <0.001 rited thrombophilia 0.002 rited thrombophilia 14 (0.03%) 22 (0.01%) 0.004 lar or connective tissue diseases 341 (0.78%) 1879 (0.86%) 0.0044 ps fetalis 8 (0.02%) 138 (0.04%) 0.004 ps fetalis 141 (0.32%) 593 (0.27%) 0.009 difform mole 141 (0.32%) 593 (0.27%) 0.006 lar or connective tissue diseases 341 (0.78%) 1.103 (3.2%) 2.187 (6.4%) 2.187 (6.4%) 2.187 (6.4%) 2.187 (6.4%) 2.187 (6.4%) 2.187 (6.4%) 2.187 (6.4%) 2.187 (6.4%) 2.187 (6.4%) 2.187 (6.4%) 2.187 (6.4%) 2.187 (6.4%) 2.187 (6.4%) 2.187 (6.4%) 2.187 (6.4%) 2.187 (6.4%) 2.187 (6.4%) 2.187 (6.4%) 2.187 (6.4%) 2.2187 (6.4%) 2.2187 (6.4\%) 2.21400000000000000000000000000000000000	ornororanics yr PIH						
ospholipid antibody syndrome or 14 (0.03%) 22 (0.01%) 0.002 rited thrombophilia ar or connective tissue diseases 341 (0.78%) 1879 (0.86%) 0.004 lar or connective tissue diseases 341 (0.78%) 1879 (0.86%) 0.004 0.002 ps fetalis ar or connective tissue diseases 341 (0.78%) 1879 (0.86%) 0.004 ps fetalis s (0.02%) 138 (0.06%) 0.001 1032 ps fetalis s (0.02%) 138 (0.06%) 0.001 4676 of difform mole 141 (0.32%) 593 (0.27%) 1006 1103 (3.2%) 5582 GDM 141 (0.32%) 593 (0.27%) 593 (0.27%) 1007 5582 c glucose metabolism 141 (0.32%) 593 (0.27%) 0.069 1103 (3.2%) 5582 c d glucose metabolism 141 (0.32%) 593 (0.27%) 0.069 1103 (3.2%) 5675 (7.8%) 11,771 c d glucose metabolism c anti-hypertensive drugs 514 (1.5%) 514 (1.7%) 5474 c anti-hypertensive drugs	ospholipid antibody syndrome or 14 (0.03%) 22 (0.01%) 0.002 rited thrombophilia ar or connective tissue diseases 341 (0.78%) 1879 (0.86%) 0.094 ar or connective tissue diseases 341 (0.78%) 1879 (0.86%) 0.094 5532 ps fetalis 82 (0.02%) 1879 (0.86%) 0.002 4676 ps fetalis 82 (0.02%) 133 (0.06%) 0.001 4676 difform mole 141 (0.32%) 593 (0.27%) 0.005 1103 (3.2%) 4676 GDM ed glucose metabolism 141 (0.32%) 593 (0.27%) 0.005 1103 (3.2%) 2575 consolin 141 (0.32%) 593 (0.27%) 0.005 1103 (3.2%) 4676 GDM ed glucose metabolism 141 (0.32%) 593 (0.27%) 0.005 11771 consolin 141 (0.32%) 593 (0.27%) 0.005 1103 (3.2%) 2575 (1.7%) didicom 140 1100 (3.2%) 579 (1.7%) 11771 continue of the distribution date. 1100 (3.2%) 1100 (3.2%) 2576 (1.7%)	nronic kidnev disease	89 (0.20%)	265 (0.12%)	< 0.001			
rited thrombophilia rited thrombophilia lar or connective tissue diseases $341 (0.78\%) = 1879 (0.86\%) = 0.094$ ps fetalis $82 (0.02\%) = 138 (0.06\%) = 0.032$ lained fetal growth restiction $89 (0.20\%) = 138 (0.06\%) = 0.0001$ lained fetal growth restiction $89 (0.20\%) = 593 (0.27\%) = 0.069$ lained fetal growth restiction $89 (0.22\%) = 593 (0.27\%) = 0.069$ lained fetal growth restiction $89 (0.22\%) = 593 (0.27\%) = 0.069$ lained fetal growth restiction $89 (0.22\%) = 593 (0.27\%) = 0.069$ reference of the set of the se	rited thrombophilia arr or connective tissue diseases $341 (0.78\%) = 1879 (0.86\%) = 0.094$ by fetalis setul test diseases $341 (0.78\%) = 1879 (0.86\%) = 0.032$ ps fetalis $8 (0.02\%) = 138 (0.06\%) = 0.001$ lained fetal growth restiction $89 (0.20\%) = 533 (0.27\%) = 0.069$ line of the setul test of the set of the set of test of the set of test of the set of test of the set of the set of the set of test of test of the set of test of	ntiphospholipid antibody syndrome or		22(0.01%)	0.002			
ar or connective tissue diseases $341 (0.78\%)$ $1879 (0.86\%)$ 0.094 ps fetalis8 (0.02\%) $82 (0.04\%)$ 0.032 lained fetal growth restiction8 (0.02\%) $82 (0.04\%)$ 0.032 lained fetal growth restiction8 (0.20\%) $138 (0.06\%)$ <0001 difform mole141 (0.32\%) $593 (0.27\%)$ 0.069 $1103 (3.2\%)$ ded glucose metabolism6 glucose metabolism $553 (0.27\%)$ $5675 (7.8\%)$ $11,771$ contribution $6 - 0.001$ $2187 (6.4\%)$ $579 (1.7\%)$ $11,771$ $6 - 0.001$ $6 - 0.009$ $1103 (3.2\%)$ 2476 $2187 (6.4\%)$ $11,771$ $6 - 0.001$ $6 - 0.001$ $11,771$ $514 (1.5\%)$ 2454 $6 - 0.001$ $6 - 0.001$ $579 (1.7\%)$ 2454 $579 (1.7\%)$ 2454 $6 - 0.001$ $6 - 0.001$ $11,710$ $514 (1.5\%)$ 2454 $6 - 0.001$ $6 - 0.001$ $6 - 0.001$ $11,790$ 2454 $6 - 0.001$ $11,700$ $11,790$ 2454 $11,790$ $6 - 0.001$ $11,790$ $11,790$ 2454 $6 - 0.001$ $11,790$ $11,790$ 2454 $6 - 0.001$ 1100 1100 1100 1100 $6 - 0.001$ 1100 1100 1100 1100 $6 - 0.001$ 1100 1100 1100 1100 $6 - 0.001$ 1100 1100 1100 1100 1000 1100 1100 1100 1100 1000 1100 1100	ar or connective tissue diseases $341 (0.78\%)$ $1879 (0.86\%)$ 0.094 ps fetalis8 (0.02\%) $82 (0.04\%)$ 0.032 lained fetal growth restiction89 (0.20\%) $138 (0.06\%)$ <0.001 lained fetal growth restiction89 (0.20\%) $593 (0.27\%)$ $103 (3.2\%)$ 4676 connole141 (0.32\%) $593 (0.27\%)$ 0.069 $1103 (3.2\%)$ 5582 connole $141 (0.32\%)$ $593 (0.27\%)$ $579 (1.7\%)$ 11771 connole $2187 (6.4\%)$ 11771 $514 (1.5\%)$ 11771 connole $2187 (6.4\%)$ 11771 $514 (1.5\%)$ 2454 connole 616 -minal 616 -minal $579 (1.7\%)$ 2454 d = gestational diabetes mellitus, ICS = inhaled corticosteroids, PIH = pregnancy-induced hypertension. 646 2464 2464 d = gestational diabetes mellitus, ICS = inhaled corticosteroids, PIH = pregnancy-induced hypertension. 6406 6406 2464 d = gestational diabetes mellitus, ICS = inhaled corticosteroids, PIH = pregnancy-induced hypertension. 6406 6406 6406 d = gestational diabetes mellitus, ICS = inhaled corticosteroids, PIH = pregnancy-induced hypertension. 6406 6406 6406 d = gestational diabetes mellitus, ICS = inhaled corticosteroids, PIH = pregnancy-induced hypertension. 6406 6406 6406 d = gestational diabetes mellitus, ICS = inhaled corticosteroids, PIH = pregnancy-induced hypertension. 6406 6406 6406 d = gestational diabetes mellitus, ICS = inhaled corticosteroids, PIH = pregnancy-i	inherited thrombophilia						
ps tetalis ps tetalis lained fetal growth restiction $82 (0.02\%) = 138 (0.06\%) = 0.032$ difform mole $141 (0.32\%) = 138 (0.06\%) = <0.001$ and the second $141 (0.32\%) = 593 (0.27\%) = 0.069$ and the second $141 (0.32\%) = 593 (0.27\%) = 0.069$ and the second $141 (0.32\%) = 593 (0.27\%) = 0.069$ and the second $141 (0.32\%) = 593 (0.27\%) = 0.069$ and the second $141 (0.32\%) = 593 (0.27\%) = 0.069$ and the second tetal second $141 (0.32\%) = 593 (0.27\%) = 0.069$ and the second tetal second $141 (0.32\%) = 593 (0.27\%) = 0.069$ and the second tetal second tetal second $141 (0.32\%) = 593 (0.27\%) = 0.069$ and the second tetal second tetal second tetal second $11,771 = 514 (1.5\%) = 0.061$ and the second tetal second tetal second $11,770 = 0.061 (1.7\%) = 0.061$ and the second tetal second tetal second $1,790 = 0.069$ and the second tetal second tetal second $1,790 = 0.069$ and the second $1,790 = 0.$	ps tetalis ps tetalis lained fetal growth restiction $82 (0.02\%) = 138 (0.06\%) = 0.032$ lained fetal growth restiction $89 (0.20\%) = 138 (0.06\%) = <0.001$ difform mole $141 (0.32\%) = 593 (0.27\%) = 0.069$ ted glucose metabolism ed glucose metabolism ed glucose metabolism i anti-hypertensive drugs i anti-hype	ascular or connective tissue diseases	341 (0.78%)	18/9 (0.86%)	0.094			
lained fetal growth restiction 89 (0.20%) 138 (0.06%) <0.001 difform mole 141 (0.32%) 593 (0.27%) 103 (3.2%) 4676 GDM 6.4%) 593 (0.27%) 0.069 1103 (3.2%) 4676 ced glucose metabolism 141 (0.32%) 593 (0.27%) 0.069 113 (71 552 ced glucose metabolism 2187 (6.4%) 558 2187 (6.4%) 558 11,771 catilitypertensive drugs 1 241 (1.5%) 0.169 11,771 514 (1.5%) 2454 idemia $d =$ gestational diabetes mellitus, ICS = inhaled corticosteroids, PIH = pregnancy-induced hypertension. 2454 579 (1.7%) 2454 $M =$ gestational diabetes mellitus, ICS = inhaled corticosteroids, PIH = pregnancy-induced hypertension. 2464 579 (1.7%) 2454 $M =$ gestational diabetes mellitus, ICS = inhaled corticosteroids, PIH = pregnancy-induced hypertension. 2464 579 (1.7%) 2454 $M =$ gestational diabetes mellitus, ICS = inhaled corticosteroids, PIH = pregnancy-induced hypertension. 2464 579 (1.7%) 2454 $M =$ gestational diabetes mellitus, ICS = inhaled corticosteroids, PIH = pregnancy-induced hyper	lained fetal growth restiction $89 (0.20\%)$ $138 (0.06\%)$ <0.001 difform mole $141 (0.32\%)$ $593 (0.27\%)$ 0.069 $1103 (3.2\%)$ 4676 GDM $630 (0.27\%)$ $593 (0.27\%)$ 0.069 $1103 (3.2\%)$ 5582 a glucose metabolism $141 (0.32\%)$ $593 (0.27\%)$ 0.069 $1103 (3.2\%)$ 557 i a glucose metabolism $141 (0.32\%)$ $593 (0.27\%)$ 0.069 $1103 (3.2\%)$ 576 i a glucose metabolism $141 (0.32\%)$ $593 (0.27\%)$ 0.069 $1103 (3.2\%)$ $2675 (7.8\%)$ $11,771$ i a stri-hypertensive drugs $11,771$ $514 (1.5\%)$ $579 (1.7\%)$ 2454 i demia 4 = gestational diabetes mellitus, ICS = inhaled corticosteroids, PIH = pregnancy-induced hypertension. 2454 $579 (1.7\%)$ 2454 A = gestational diabetes mellitus, ICS = inhaled corticosteroids, PIH = pregnancy-induced hypertension. 2464 $11,7\%$ A = gestational diabetes mellitus, ICS = inhaled corticosteroids, PIH = pregnancy-induced hypertension. 2454 $579 (1.7\%)$ 2464 A = gestational diabetes mellitus, ICS = inhaled corticosteroids, PIH = pregnancy-induced hypertension. 2464 </td <td>ydrops fetalis</td> <td>8 (0.02%)</td> <td></td> <td>0.032</td> <td></td> <td></td> <td></td>	ydrops fetalis	8 (0.02%)		0.032			
$ \begin{array}{c} \mbox{difform mole} & 141 (0.32\%) & 593 (0.27\%) & 0.069 \\ \mbox{GDM} & \mbox{GDM} & 103 (3.2\%) & 582 \\ \mbox{ed glucose metabolism} & \mbox{constantian} & constant$	difform mole $141 (0.32\%)$ $593 (0.27\%)$ 0.069 $1103 (3.2\%)$ 4676 GDM GDM $2187 (6.4\%)$ 5582 ed glucose metabolism $2187 (6.4\%)$ 5782 eradiplotese metabolism $2575 (7.8\%)$ $11,771$ i anti-hypertensive drugs $579 (1.7\%)$ 2454 i demia $6 = estational diabetes mellitus, ICS = inhaled corticosteroids, PIH = pregnancy-induced hypertension. 2454 A = gestational diabetes mellitus, ICS = inhaled corticosteroids, PIH = pregnancy-induced hypertension. 2454 M = gestational diabetes mellitus, ICS = inhaled corticosteroids, PIH = pregnancy-induced hypertension. 2454 M = controv date 0.000 + 0.000 + 0.000 + 0.000 + 0.000 + 0.000 + 0.000 + 0.000 + 0.000 + 0.0$	nexplained fetal growth restiction	89 (0.20%)		< 0.001			
$ \begin{array}{c} \text{GDM} \\ \text{ed glucose metabolism} \\ \text{ed glucose metabolism} \\ \text{ed glucose metabolism} \\ \text{ension} \\ \text{fension} \\ \text{fension} \\ \text{fension} \\ \text{fension} \\ \text{fension} \\ \text{fidemia} \\ \text{for the transve drugs} \\ for the transve drug$	$ \begin{array}{c} \text{GDM} \\ \text{ed glucose metabolism} \\ \text{ed glucose metabolism} \\ \text{ed glucose metabolism} \\ \text{ed glucose metabolism} \\ \text{fanti-hypertensive drugs} \\ \text$	ydatidiform mole	141 (0.32%)		0.069			
ed glucose metabolism 2187 (6.4%) 5582 tension 2187 (6.4%) 5582 tension 2675 (7.8%) 11,771 anti-hypertensive drugs 579 (1.7%) 11,771 idemia 579 (1.7%) 2454 d = gestational diabetes mellitus, ICS = inhaled corticosteroids, PIH = pregnancy-induced hypertension. 2454 te at initiation date. 2454 thin 40 weeks prior to delivery date (during pregnancy). m cohort entry date.	ed glucose metabolism 2187 (6.4%) 5582 tension 2187 (6.4%) 5582 tension 2675 (7.8%) 11,771 anti-hypertensive drugs 579 (1.7%) 11,771 idemia 579 (1.7%) 2454 de gestational diabetes mellitus, ICS = inhaled corticosteroids, PIH = pregnancy-induced hypertension. 2454 te at initiation date. 2454 thin 40 weeks prior to delivery date (during pregnancy). 2454 m cohort entry date.	For GDM				1103(3.2%)	4676 (2.7%)	< 0.001
tension 2675 (7.8%) 11,771 514 (1.5%) 11,771 514 (1.5%) 1848 579 (1.7%) 2454 A = gestational diabetes mellitus, ICS = inhaled corticosteroids, PIH = pregnancy-induced hypertension. A = gestational diabetes mellitus, ICS = inhaled corticosteroids, PIH = pregnancy-induced hypertension. A = gestational diabetes mellitus, ICS = inhaled corticosteroids, PIH = pregnancy-induced hypertension. A = gestational diabetes mellitus, ICS = inhaled corticosteroids, PIH = pregnancy-induced hypertension.	tension 2675 (7.8%) 11,771 214 (1.5%) 11,771 514 (1.5%) 1848 579 (1.7%) 2454 4 = gestational diabetes mellitus, ICS = inhaled corticosteroids, PIH = pregnancy-induced hypertension. A = gestational diabetes mellitus, ICS = inhaled corticosteroids, PIH = pregnancy-induced hypertension. a = initiation date. A = weeks prior to delivery date (during pregnancy). m cohort entry date.	npaired glucose metabolism				2187 (6.4%)	5582(3.3%)	< 0.001
 a thi-hypertensive drugs a thi-hypertensive drugs a thi-hypertensive drugs a thi-hypertensive drugs a thi-gestational diabetes mellitus, ICS = inhaled corticosteroids, PIH = pregnancy-induced hypertension. a thi a thi-a th	 a thi-hypertensive drugs a thi-hypertensive drugs a thi-hypertensive drugs a thi-hypertensive a thi-hypertension a thi-hypertension a thi-to weeks prior to delivery date (during pregnancy). 	[ypertension					11,771 (6.9%)	< 0.001
idemia 579 (1.7%) 2454 <i>A</i> = gestational diabetes mellitus, ICS = inhaled corticosteroids, PIH = pregnancy-induced hypertension. <i>A</i> = gestation date. <i>A</i> = to initiation date. <i>A</i> = to delivery date (during pregnancy). <i>B</i> = cohort entry date. <i>B</i> = cohort entry date. <i></i>	idemia 579 (1.7%) 2454 <i>A</i> = gestational diabetes mellitus, ICS = inhaled corticosteroids, PIH = pregnancy-induced hypertension. <i>A</i> = de at initiation date. hin 40 weeks prior to delivery date (during pregnancy). m cohort entry date.	Jse of anti-hypertensive drugs					1848(1.1%)	< 0.001
COS GDM = gestational diabetes mellitus, ICS = inhaled corticosteroids, PIH = pregnancy-induced hypertension. *Age at initiation date. *Within 40 weeks prior to delivery date (during pregnancy). #From cohort entry date.	COS GDM = gestational diabetes mellitus, ICS = inhaled corticosteroids, PIH = pregnancy-induced hypertension. * Age at initiation date. †Wittin 40 weeks prior to delivery date (during pregnancy). ‡From cohort entry date.)yslipidemia				579 (1.7%)		< 0.001
GDM = gestational diabetes mellitus. ICS = inhaled corticosteroids, PIH = pregnancy-induced hypertension. *Age at initiation date. [†] Within 40 weeks prior to delivery date (during pregnancy). [‡] From cohort entry date.	GDM = gestational diabetes mellitus, ICS = inhaled corticosteroids, PIH = pregnancy-induced hypertension. *Age at initiation date. [†] Within 40 weeks prior to delivery date (during pregnancy).	COŜ						
GiDM = gestational diabetes mellitus, ICS = inhaled corticosteroids, PIH = pregnancy-induced hypertension. *Age at initiation date. [†] Within 40 weeks prior to delivery date (during pregnancy). [‡] From cohort entry date.	GDM = gestational diabetes mellitus, ICS = inhaled corticosteroids, PIH = pregnancy-induced nypertension. *Age at initiation date. [†] Within 40 weeks prior to delivery date (during pregnancy).							
[†] Within 40 weeks prior to delivery date (during pregnancy). [‡] From cohort entry date.	[†] Within 40 weeks prior to delivery date (during pregnancy). [‡] From cohort entry date.	GUM = gestational diabetes mellitus, IC * Age at initiation date.	S = inhaled corticosteroids, PI	H = pregnancy-induced hypertensic	Jn.			
*From cohort entry date.	+From cohort entry date.	[†] Within 40 weeks prior to delivery date	(during pregnancy).					
		⁺ From cohort entry date.						
· · · · · · · · · · · · · · · · · · ·								

4 www.md-journal.com

Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.

	PIH (N = 43,908)	Control (N = 219,534)	Р	GDM (N = 34,190)	Control (N = 170,934)	Р
	n (%)	n (%)	Value	n (%)	n (%)	Value
During pregnancy Inhaler medication use [*]						
Neither ICS nor LABA	43,821 (99.80%)	219,174 (99.84%)	0.226	34,121 (99.80%)	170,580 (99.79%)	0.656
ICS with LABA	69 (0.16%)	274 (0.12%)		47 (0.14%)	260 (0.15%)	
ICS without LABA	18 (0.04%)	86 (0.04%)		22 (0.06%)	94 (0.05%)	
$ICS MPR^{\dagger}$				· · · ·		0.126
0	43,733 (99.60%)	218,610 (99.58%)	0.001	34,053 (99.60%)	170,116 (99.52%)	
0-0.3	135 (0.31%)	814 (0.37%)		114 (0.33%)	695 (0.41%)	
>0.3	40 (0.09%)	110 (0.05%)		23 (0.07%)	123 (0.07%)	
ICS cumulative dose [†]					· /	
Mean (SD)	62.5 ± 1678.0	43.4 ± 1248.6	<001	50.0 ± 1277.5	57.2 ± 1418.5	
0	43,733 (99.60%)	218,610 (99.58%)	0.013	34,053 (99.60%)	170,116 (99.52%)	0.125
0-14,999 μg	99 (0.23%)	628 (0.29%)		83 (0.24%)	515 (0.30%)	
$\geq 15,000 \mu g$	76 (0.17%)	296 (0.13%)		54 (0.16%)	303 (0.18%)	
LTRA use [*]	7 (0.02%)	95 (0.04%)	0.008	14 (0.04%)	79 (0.05%)	0.672
Systemic corticosteroid use [‡]	84 (0.19%)	324 (0.15%)	0.033	58 (0.17%)	307 (0.18%)	0.688
SABA prescription duration in n	nonths [§]					
Mean (SD)	0.0 ± 0.09	0.0 ± 0.09	<001	0.0 ± 0.2	0.0 ± 0.1	
0	43,831 (99.82%)	219,140 (99.82%)	0.362	34,129 (99.82%)	170,568 (99.79%)	0.228
1	60 (0.14%)	333 (0.15%)		53 (0.16%)	298 (0.17%)	
>1	17 (0.04%)	61 (0.03%)		8 (0.02%)	68 (0.04%)	
Before pregnancy						
Inhaler medication use						
Neither ICS nor LABA	43,803 (99.76%)	219,035 (99.77%)	0.638	34,095 (99.72%)	170,427 (99.70%)	0.802
ICS with LABA	86 (0.20%)	422 (0.19%)		79 (0.23%)	415 (0.24%)	
ICS without LABA	19 (0.04%)	77 (0.04%)		16 (0.05%)	92 (0.05%)	
ICS MPR [¶]						
0	43,672 (99.46%)	218,293 (99.43%)	0.423	33,941 (99.27%)	169,752 (99.31%)	0.508
0-3	198 (0.45%)	1004 (0.46%)		208 (0.61%)	959 (0.56%)	
>0.3	38 (0.09%)	237 (0.11%)		41 (0.12%)	223 (0.13%)	
ICS cumulative dose [¶]						
Mean (SD)	4638.6 ± 209442.02	4994.3 ± 228636.11	0.763	5386.3 ± 227254.0	7317.8 ± 280767.0	
0	43,672 (99.46%)	218,293 (99.43%)	0.387	33,941 (99.27%)	169,752 (99.31%)	0.452
0–14,999 µg	143 (0.33%)	802 (0.37%)		159 (0.47%)	714 (0.42%)	
≥15,000 µg	93 (0.21%)	439 (0.20%)		90 (0.26%)	468 (0.27%)	
LTRA use	44 (0.10%)	187 (0.09%)	0.340	41 (0.12%)	192 (0.11%)	0.706
Systemic corticosteroid use#	52 (0.10%)	301 (0.14%)	0.321	43 (0.13%)	285 (0.17%)	0.074
SABA prescription duration in n	nonths ^{**}					
Mean (SD)	0.3 ± 14.74	0.2 ± 16.84	0.212	0.5 ± 37.6	0.2 ± 12.8	
0	43,784 (99.72%)	218,968 (99.74%)	0.571	34,086 (99.70%)	170,402 (99.69%)	0.938
1	96 (0.22%)	450 (0.20%)		81 (0.24%)	421 (0.25%)	
>1	28 (0.06%)	116 (0.05%)		23 (0.07%)	111 (0.06%)	

ICS = inhaled corticosteroids, LABA = long-acting inhaled β 2-agonists, LTRA = leukotriene receptor antagonist, MPR = medication possession ratio, PIH = pregnancy-induced hypertension, SABA = short-acting inhaled β 2-agonists.

Prescription for at least 30 days within 180 days prior to event date.

Within 180 days prior to event date.

¹140 mg (equivalent to 20 mg/day for 7 days) or greater within 180 days prior to event date.

[§]Prescription for at least 1 month (30 days) within 180 days prior to event date.

^{||}Prescription for at least 1 month (30 days) within 180 days before pregnancy.

[¶]Within 180 days prior to before pregnancy.

 $^{\#}140 \text{ mg}$ (equivalent to 20 mg/day for 7 days) or greater within 180 days prior to before pregnancy.

**Within 180 days prior to before pregnancy.

ICS use and development of PIH. ICS use was not associated with an increased risk of GDM.

Our study is somewhat different from previous studies that reported no relationship between asthma drugs, including ICS,

and PIH. However, only a few studies investigated the relation-ship between ICS use and the risk of PIH.^{1,2,21,22} A prospective cohort study reported that the ICSs-only group did not increase the risk of preeclampsia.¹ One randomized trial did not find any

TABLE 3. Risk of PIH According to ICS Use	According to ICS	Use								
	PIH $(n = 43,908)$ Control $(n =$	Control (n = 219,534)	Unadjusted	pa	Model 1		Model 2	5	Model 3	
Category	n (%)	n (%)	OR (95% CI)	P Value	OR (95% CI)	P Value	OR (95% CI)	P Value	OR (95% CI)	P Value
Inhaler medication use [*] No ICS	43,8	219,174 (99.84%)	1		-		-		1	
ICS Inhaler medication use	*	360 (0.16%)	1.20(0.78 - 1.85)	0.397	1.33 (1.02–1.72)	0.032	1.29(0.99 - 1.68)	0.060	1.27 (0.98–1.66)	0.074
No ICS	43,821 (99.80%)	219,174 (99.84%)	1		1		1		1	
ICS with LABA	69 (0.16%)	274 (0.12%)	1.28 (0.97-1.69)	0.079	1.40 (1.05–1.87)	0.023	1.34 (1.00-1.80)	0.049	1.34 (1.00-1.80)	0.054
ICS without LABA	18 (0.04%)	86 (0.04%)	1.06 (0.64–1.77)	0.810	1.12 (0.67–1.87)	0.669	1.13 (0.67–1.89)	0.656	$1.1 \ (0.65 - 1.85)$	0.733
0	43,733 (99.60%)	218,610 (99.58%)	1		1		1		1	
0-0.3	135 (0.31%)	814 (0.37%)	$0.83 \ (0.69 - 1.00)$	0.051	0.85 (0.70-1.03)	0.097	0.84 (0.70-1.02)	0.084	$0.85 \ (0.7 - 1.03)$	0.100
>0.3	40 (0.09%)	110 (0.05%)	1.90 (1.30-2.79)	0.001	2.18 (1.45-3.29)	< 0.001	2.11 (1.38-3.23)	< 0.001	2.32 (1.5–3.58)	< 0.001
ICS cumulative dose [†]										
0	43,733 (99.60%)	218,610 (99.58%)	1		1		1		1	
0–14,999 µg	99 (0.23%)	628 (0.29%)	0.79(0.64 - 0.98)	0.030	0.80(0.64 - 0.99)	0.040	0.79 (0.64 - 0.99)	0.037	$0.80 \ (0.64 - 0.99)$	0.042
≥15,000 µg	76 (0.17%)	296 (0.13%)	1.30(1.00-1.69)	0.053	1.40 (1.06–1.85)	0.016	1.36 (1.02–1.81)	0.034	1.34 (1.01–1.79)	0.043
CI = confidence interval, ICS = inhaled corticosteroids, LA PIH = pregnancy-induced hypertension, SABA = short-acting Model 1: Adjusted by other concomitant medication used Model 2: Adjusted by other concomitant medication used du syndrome or inherited thrombophilia, vascular or connective tis utilization. Model 3: Adjusted by other concomitant medication used du syndrome or inherited thrombophilia, vascular or connective ti "Prescription for 30 days or longer within 180 days before "Within 180 days before event date."	CI = confidence interval, ICS = inhaled corticosteroids, LAI H = pregnancy-induced hypertension, SABA = short-acting i Model 1: Adjusted by other concomitant medication used dur Model 2: Adjusted by other concomitant medication used dur ndrome or inherited thrombophilia, vascular or connective tiss lization. Model 3: Adjusted by other concomitant medication used dur ndrome or inherited thrombophilia, vascular or connective ti lization and medication before pregnancy (ICS/LABA, ICS *Prescription for 30 days or longer within 180 days before 'Within 180 days before event date.	CI = confidence interval, ICS = inhaled corticosteroids, LABA = long-acting inhaled β2-agonists, LTRA = leukotriene receptor antagonist, MPR = medication possession ratio, OR = odds ratio, PIH = pregnancy-induced hypertension, SABA = short-acting inhaled β2-agonists. Model 1: Adjusted by other concomitant medication used during pregnancy (LTRA, oral corticosteroids, SABA). Model 2: Adjusted by other concomitant medication used during pregnancy (LTRA, oral corticosteroids, SABA), age, PIH in a previous pregnancy, chronic kidney disease, antiphospholipid antibody syndrome or inherited thrombophilia, vascular or connective tissue disease, diabetes mellitus, hydrops fetalis, unexplained fetal growth restriction, hydatidiform mole, multiple pregnancy, and health care utilization. Model 3: Adjusted by other concomitant medication used during pregnancy (LTRA, oral corticosteroids, SABA), age, PIH in a previous pregnancy, chronic kidney disease, antiphospholipid antibody syndrome or inherited thrombophilia, vascular or connective tissue disease, diabetes mellitus, hydrops fetalis, unexplained fetal growth restriction, hydatidiform mole, multiple pregnancy, health care utilization. Model 3: Adjusted by other concomitant medication used during pregnancy (LTRA, oral corticosteroids, SABA), age, PIH in a previous pregnancy, chronic kidney disease, antiphospholipid antibody syndrome or inherited thrombophilia, vascular or connective tissue disease, diabetes mellitus, hydrops fetalis, unexplained fetal growth restriction, hydatidiform mole, multiple pregnancy, health care "Prescription for 30 days or longer within 180 days before event date." "Prescription for 30 days or longer within 180 days before event date.	ABA = long-acting inhaled β2-agonists, LTRA = leukott i inhaled β2-agonists. during pregnancy (LTRA, oral corticosteroids, SABA), age seue disease, diabetes mellitus, hydrops fetalis, unexplaine uring pregnancy (LTRA, oral corticosteroids, SABA), age tissue disease, diabetes mellitus, hydrops fetalis, unexplaine tissue disease, diabetes mellitus hydrops fetalis, unexplaine tissue disease hydrops f	agonists, L' corticoster rrticosteroid nydrops feta rrticosteroid , hydrops f LTRA, ora	IRA = leukotriene re oids, SABA). s, SABA), age, PIH i lis, unexplained fetal is, SABA), age, PIH i etalis, unexplained fe etalis, unexplained fe	ceptor ant a previou growth rest a previou tal growth BA).	igonist, MPR = mee s pregnancy, chronic riction, hydatidiforr s pregnancy, chronic restiction, hydatidif	lication pos c kidney dise n mole, mult c kidney dise ôrm mole, n	session ratio, OR = (2ase, antiphospholipi tiple pregnancy, and l 2ase, antiphospholipi nultiple pregnancy, h	d antibody health care d antibody antibody nealth care

TABLE 4. Risk of GDM According to ICS Use	M According to ICS	Use								
	GDM $(N = 34,190)$ Control (N)	Control $(N = 170,934)$	Unadjusted	pa	Model 1		Model 2		Model 3	
Category	n (%)	n (%)	OR (95% CI)	P Value	OR (95% CI)	P Value	OR (95% CI)	P Value	OR (95% CI)	P Value
Inhaler medication use No ICS ICS	* 34,121 (99.80%) 69 (0.20%)	170,580 (99.79%) 354 (0.20%)	1 0.9 (0.72–1.25)	0.710	1 1 (0.77–1.38)	0.818	1 1 (0.76–1.37)	0.904	1 1 (0.77–1.4)	0.823
Inhaler medication use [*] No ICS ICS with LABA ICS without LABA	34,121 (99.80%) 47 (0.14%) 22 (0.06%)	170,580 (99.79%) 260 (0.15%) 94 (0.05%)	$\begin{array}{c}1\\0.9\ (0.63{-}1.22)\\1.1\ (0.71{-}1.83)\end{array}$	0.433 0.585	$\begin{matrix} 1\\1 & (0.69{-}1.37)\\1.2 & (0.74{-}1.93)\end{matrix}$	0.856 0.465	$\begin{array}{c}1\\0.9\ (0.61{-}1.25)\\1.2\ (0.71{-}1.93)\end{array}$	0.463 0.545	$\begin{matrix} 1\\ 0.9 & (0.62{-}1.26)\\ 1.2 & (0.72{-}1.99) \end{matrix}$	0.486 0.492
0 $0 < \leq 0.3$ > 0.3 TCS multitive doub	34,053 (99.60%) 114 (0.33%) 23 (0.07%)	170,116 (99.52%) 695 (0.41%) 123 (0.07%)	$\begin{array}{c}1\\0.8\;(0.62{-}1)\\0.8\;(0.62{-}1.15)\end{array}$	0.049 0.281	$\begin{array}{c}1\\0.8\ (0.66{-}1.01)\\1\ (0.6{-}1.63)\end{array}$	0.065 0.971	$\begin{array}{c}1\\0.8\ (0.61{-}0.95)\\1\ (0.6{-}1.66)\end{array}$	0.017 0.982	$\begin{array}{c}1\\0.8\ (0.65{-}1.01)\\1\ (0.6{-}1.74)\end{array}$	0.058 0.927
1C3 Cumutative dose 0 2-14,999 μg ≥15,000 μg	34,053 (99.60%) 83 (0.24%) 54 (0.16%)	170,116 (99.52%) 515 (0.30%) 303 (0.18%)	$\begin{array}{c}1\\0.8\;(0.65{-}0.98)\\0.9\;(0.56{-}1.43)\end{array}$	0.029 0.641	$\begin{array}{c}1\\0.8\ (0.63\!-\!1.03)\\0.9\ (0.65\!-\!1.25)\end{array}$	$0.079 \\ 0.534$	$\begin{array}{c}1\\0.8\;(0.64{-}1.04)\\0.9\;(0.62{-}1.21)\end{array}$	0.097 0.412	$\begin{array}{c}1\\0.8\ (0.63\!-\!1.03)\\0.9\ (0.63\!-\!1.23)\end{array}$	0.079 0.464
CI = confidence interval, GDM = ge possession ratio, OR = odds ratio, SAF Model 1: adjusted by other concomi Model 2: adjusted by other concomit metabolism, hypertention, anti-HTN di Model 3: adjusted by other concomit metabolism, hypertention, anti-HTN di *Prescription for 30 days or longer 'Within 180 days before event date.	al, GDM = gestational ddds ratio, SABA = shor other concomitant medic ther concomitant medic 1, anti-HTN drug, dysli other concomitant medic 1, anti-HTN drug, dysli ays or longer within 18 or event date.	CI = confidence interval, GDM = gestational diabetes mellitus, ICS = inhaled corticosteroid, LABA = long-acting inhaled β2 agonists, LTRA = leukotriene receptor antagonist, MPR = medication possession ratio, OR = odds ratio, SABA = short-acting inhaled β2-agonists. Model 1: adjusted by other concomitant medication used during pregnancy (LTRA, OCS, SABA). Model 2: adjusted by other concomitant medication used during pregnancy (LTRA, OCS, SABA), age, asthma history, PIH in a during pregnancy, GDM, PIH, impaired glucose metabolism, hypertention, anti-HTN drug, dyslipidemia, PCOS, and health care utilization. Model 3: adjusted by other concomitant medication used during pregnancy (LTRA, OCS, SABA), age, asthma history, PIH in a during pregnancy, GDM, PIH, impaired glucose metabolism, hypertention, anti-HTN drug, dyslipidemia, PCOS, and health care utilization. Model 3: adjusted by other concomitant medication used during pregnancy (LTRA, OCS, SABA), age, asthma history, PIH in a during pregnancy, instory of pregnancy, GDM, PIH, impaired glucose metabolism, hypertention, anti-HTN drug, dyslipidemia, PCOS, and health care utilization. Model 3: adjusted by other concomitant medication used during pregnancy (LTRA, OCS, SABA), age, asthma history, PIH in a during pregnancy, GDM, PIH, impaired glucose metabolism, hypertention, anti-HTN drug, dyslipidemia, PCOS, and health care utilization.	aled corticosteroid, s. hcy (LTRA, OCS, S v (LTRA, OCS, SAI care utilization. v (LTRA, OCS, SAI care utilization and	LABA = loi ABA). 3A), age, ast 3A), age, ast 1 medication	ng-acting inhaled β hma history, PIH ii hma history, PIH ii before pregnancy	.2 agonists, 1 a during p 1 a during p (ICS/LAB)	LTRA = leukotrien regnancy, history of regnancy, history of A, ICS MPR or ICS	e receptor a pregnancy, pregnancy, cumulativ	ntagonist, MPR = n GDM, PIH, impairt GDM, PIH, impairc e dose, LTRA, OCS	edication ed glucose ed glucose s, SABA).

significant differences in obstetric outcomes including PIH between inhaled beclomethasone group and theophylline group.²² A larger nested case-control study using administrative databases in Quebec demonstrated that ICSs did not increase the risk of PIH.² However, these studies have several weak points in supporting the neutral effect of ICSs on PIH. First, each study included only pregnant women with asthma. Because asthma itself increases the risk of PIH,²³ the effects of ICSs, which are the principal asthma-controller medications, on PIH could have been weakened. Our nested case-control study using a nationwide database included all pregnant women with or without asthma. Second, several studies had only small numbers of PIH cases.^{21,22} Our study analyzed more than 40,000 cases with PIH. Third, although previous studies did not find any statistically significant increases in PIH risk among ICS users, the majority showed trends that ICSs increase the risk of PIH. For example, 1 prospective study demonstrated that 10.9% of ICS users versus 7.8% of individuals who did not use ICSs experienced PIH, while a previous nested case-control study computed an aOR for PIH of 1.06 with ICS use, with a prevalence of PIH among ICS users of 0.20%, similar to our results.^{1,2}

We also showed that no significant increase in the risk of GDM was observed among pregnant women who were prescribed ICS. These results could be explained by various factors. First, unlike systemic corticosteroid treatment, ICSs may have little impact on serum glucose levels.³⁴ Although several studies reported a positive association between ICS and DM,^{34–39} other studies found contradicting results.^{34,36,37,39} Second, a relatively short duration of ICS treatment during pregnancy (at most 10 months) could be associated with fewer effects. In fact, studies showed that total systemic glucocorticoid dose and duration could influence glucocorticoid-induced hyperglycemia.⁹ However, it remains unclear whether or not ICS dose and duration are significantly associated with the development of hyperglycemia. An analysis evaluating randomized trials conducted over 4 years did not find any significant relationship between DM/hyperglycemia and ICS.36

Our study has several advantages. Most of all, as it was based on a nationwide insurance claims database, the likelihood of selection bias is minimal²⁸ and relatively great number of cases could be used. Also, because we included not only women with asthma but also nonasthmatic pregnant women, the possibility of masking the risk of PIH by asthma itself, as mentioned above, was avoided.²³ In addition, a large prospective cohort study showed that severe asthma is significantly associated with GDM in multivariate analysis,⁴⁰ which suggests that asthma may also be a risk factor for GDM. Therefore, the effect of ICS on GDM may have been also weakened in an analysis only with asthmatic women. Furthermore, various possible confounders including drugs used during and before pregnancy and comorbidities were adjusted in the multivariate analyses for a better examination of the relationships between ICS use and the risk of PIH and GDM.

We should acknowledge limitations. First, the definitions of PIH and GDM were based only on ICD-10 codes. However, thanks to the coverage of national health insurance, almost all pregnant women in Korea undergo PIH and GDM screening during pregnancy. In fact, there was no difference in the number of visits to obstetricians between cases and controls in our studies. Second, third, we could not find the exact biological mechanism by which ICS increase the risk of PIH. Vitamin D deficiency might be a link. It has been reported that glucocorticoid use is associated with low 25-hydroxyvitamin D levels,⁴¹ and that low vitamin D levels are associated with the risk of preeclampsia.⁴²

Our data should be applied cautiously to the management of pregnant women with asthma. The use of ICSs may reduce the risk of exacerbation among pregnant women with asthma without an increase in adverse pregnancy outcomes.⁴³ Therefore, 1 guideline stresses that it is safer for pregnant women with asthma to be treated with asthma drugs than to have asthma symptoms and exacerbation.⁴⁴ We do not think that ICSs should be avoided due to the risk of PIH based on our study. Our study included all pregnant women with or without asthma because asthma itself has been regarded as a risk factor for PIH.²³ In addition, we also could not identify the population most prone to the risk. However, our results can be summarized in a statement that although few drugs have definitely proven teratogenic in humans, no drug can be considered completely safe.⁴⁵

In conclusion, our nationwide nested case-control studies showed that ICS use is not associated with an increased risk of PIH and GDM. However, the possibility of increased risk of PIH by ICS could not be excluded. Further studies are needed.

REFERENCES

- Schatz M, Zeiger RS, Harden K, et al. The safety of asthma and allergy medications during pregnancy. *J Allergy Clin Immunol*. 1997;100:301–306.
- Martel MJ, Rey E, Beauchesne MF, et al. Use of inhaled corticosteroids during pregnancy and risk of pregnancy induced hypertension: nested case-control study. *BMJ*. 2005;330:230.
- Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol. 2000;183:S1–S22.
- Weinstein SP, Wilson CM, Pritsker A, et al. Dexamethasone inhibits insulin-stimulated recruitment of GLUT4 to the cell surface in rat skeletal muscle. *Metabolism*. 1998;47:3–6.
- Ruzzin J, Wagman AS, Jensen J. Glucocorticoid-induced insulin resistance in skeletal muscles: defects in insulin signalling and the effects of a selective glycogen synthase kinase-3 inhibitor. *Diabetologia*. 2005;48:2119–2130.
- Buren J, Lai YC, Lundgren M, et al. Insulin action and signalling in fat and muscle from dexamethasone-treated rats. *Arch Biochem Biophys.* 2008;474:91–101.
- Henriksen JE, Alford F, Vaag A, et al. Intracellular skeletal muscle glucose metabolism is differentially altered by dexamethasone treatment of normoglycemic relatives of type 2 diabetic patients. *Metabolism.* 1999;48:1128–1135.
- Ekstrand A, Schalin-Jantti C, Lofman M, et al. The effect of (steroid) immunosuppression on skeletal muscle glycogen metabolism in patients after kidney transplantation. *Transplantation*. 1996;61:889–893.
- Kwon S, Hermayer KL. Glucocorticoid-induced hyperglycemia. Am J Med Sci. 2013;345:274–277.
- Clore JN, Thurby-Hay L. Glucocorticoid-induced hyperglycemia. Endocr Pract. 2009;15:469–474.
- Pagano G, Cavallo-Perin P, Cassader M, et al. An in vivo and in vitro study of the mechanism of prednisone-induced insulin resistance in healthy subjects. *J Clin Invest.* 1983;72:1814–1820.
- Group HSCR, Metzger BE, Lowe LP, et al. Hyperglycemia and adverse pregnancy outcomes. N Engl J Med. 2008;358:1991–2002.
- Dodd JM, Crowther CA, Antoniou G, et al. Screening for gestational diabetes: the effect of varying blood glucose definitions in the prediction of adverse maternal and infant health outcomes. *Aust N Z J Obstet Gynaecol.* 2007;47:307–312.
- 14. Jensen DM, Damm P, Sorensen B, et al. Clinical impact of mild carbohydrate intolerance in pregnancy: a study of 2904 nondiabetic

Danish women with risk factors for gestational diabetes mellitus. *Am J Obstet Gynecol.* 2001;185:413–419.

- 15. Ferrara A, Weiss NS, Hedderson MM, et al. Pregnancy plasma glucose levels exceeding the American Diabetes Association thresholds, but below the National Diabetes Data Group thresholds for gestational diabetes mellitus, are related to the risk of neonatal macrosomia, hypoglycaemia and hyperbilirubinaemia. *Diabetologia*. 2007;50:298–306.
- Metzger BE, Buchanan TA, Coustan DR, et al. Summary and recommendations of the Fifth International Workshop-Conference on Gestational Diabetes Mellitus. *Diabetes Care.* 2007;30(Suppl 2):S251–260.
- Rocklin RE. Asthma, asthma medications and their effects on maternal/fetal outcomes during pregnancy. *Reprod Toxicol.* 2011;32:189–197.
- Patton JS, Fishburn CS, Weers JG. The lungs as a portal of entry for systemic drug delivery. *Proc Am Thorac Soc.* 2004;1:338–344.
- Todd GR, Acerini CL, Buck JJ, et al. Acute adrenal crisis in asthmatics treated with high-dose fluticasone propionate. *Eur Respir* J. 2002;19:1207–1209.
- Holme J, Tomlinson JW, Stockley RA, et al. Adrenal suppression in bronchiectasis and the impact of inhaled corticosteroids. *Eur Respir* J. 2008;32:1047–1052.
- Rahimi R, Nikfar S, Abdollahi M. Meta-analysis finds use of inhaled corticosteroids during pregnancy safe: a systematic meta-analysis review. *Hum Exp Toxicol Aug.* 2006;25:447–452.
- Dombrowski MP, Schatz M, Wise R, et al. Randomized trial of inhaled beclomethasone dipropionate versus theophylline for moderate asthma during pregnancy. *Am J Obstet Gynecol Mar.* 2004;190:737–744.
- Murphy VE, Namazy JA, Powell H, et al. A meta-analysis of adverse perinatal outcomes in women with asthma. *BJOG Oct.* 2011;118:1314–1323.
- Braman SS. Postinfectious cough: ACCP evidence-based clinical practice guidelines. *Chest Jan.* 2006;129(1 Suppl):138S–146S.
- Brightling CE. Chronic cough due to nonasthmatic eosinophilic bronchitis: ACCP evidence-based clinical practice guidelines. *Chest Jan.* 2006;129(1 Suppl):116S–121S.
- Refuerzo JS, Garg A, Rech B, et al. Continuous glucose monitoring in diabetic women following antenatal corticosteroid therapy: a pilot study. Am J Perinatol May. 2012;29:335–338.
- Gurbuz A, Karateke A, Ozturk G, et al. Is 1-hour glucose screening test reliable after a short-term administration of antenatal betamethasone? *Am J Perinatol Oct.* 2004;21:415–420.
- Lee CH, Kim K, Hyun MK, et al. Use of inhaled corticosteroids and the risk of tuberculosis. *Thorax Dec.* 2013;68:1105–1113.
- Park YT, Yoon JS, Speedie SM, et al. Health insurance claim review using information technologies. *Healthc Inform Res Sep.* 2012;18:215–224.

- Lee CH, Hyun MK, Jang EJ, et al. Inhaled corticosteroid use and risks of lung cancer and laryngeal cancer. *Respir Med Aug.* 2013;107:1222–1233.
- Kim J, Lee E, Lee T, et al. Economic burden of acute coronary syndrome in South Korea: a national survey. *BMC Cardiovasc Disord*. 2013;13:55.
- Kim S, Kim J, Kim K, et al. Healthcare use and prescription patterns associated with adult asthma in Korea: analysis of the NHI claims database. *Allergy Nov.* 2013;68:1435–1442.
- Boulet LP, Becker A, Berube D, et al. Canadian Asthma Consensus Report, 1999. Canadian Asthma Consensus Group. *CMAJ*. 1999;161(11 Suppl):S1–S61.
- Blackburn D, Hux J, Mamdani M. Quantification of the risk of corticosteroid-induced diabetes mellitus among the elderly. J Gen Intern Med Sep. 2002;17:717–720.
- Suissa S, Kezouh A, Ernst P. Inhaled corticosteroids and the risks of diabetes onset and progression. Am J Med Nov. 2010;123:1001– 1006.
- O'Byrne PM, Rennard S, Gerstein H, et al. Risk of new onset diabetes mellitus in patients with asthma or COPD taking inhaled corticosteroids. *Respir Med Nov.* 2012;106:1487–1493.
- Dendukuri N, Blais L, LeLorier J. Inhaled corticosteroids and the risk of diabetes among the elderly. *Br J Clin Pharmacol Jul.* 2002;54:59–64.
- Slatore CG, Bryson CL, Au DH. The association of inhaled corticosteroid use with serum glucose concentration in a large cohort. *Am J Med May.* 2009;122:472–478.
- Faul JL, Wilson SR, Chu JW, et al. The effect of an inhaled corticosteroid on glucose control in type 2 diabetes. *Clin Med Res.* 2009;7:14–20.
- Dombrowski MP, Schatz M, Wise R, et al. Asthma during pregnancy. Obstet Gynecol. 2004;103:5–12.
- Skversky AL, Kumar J, Abramowitz MK, et al. Association of glucocorticoid use and low 25-hydroxyvitamin D levels: results from the National Health and Nutrition Examination Survey (NHANES): 2001-2006. J Clin Endocrinol Metab. 2011;96:3838–3845.
- Tabesh M, Salehi-Abargouei A, Tabesh M, et al. Maternal vitamin D status and risk of pre-eclampsia: a systematic review and metaanalysis. J Clin Endocrinol Metab. 2013;98:3165–3173.
- Murphy VE, Clifton VL, Gibson PG. Asthma exacerbations during pregnancy: incidence and association with adverse pregnancy outcomes. *Thorax*. 2006;61:169–176.
- Dombrowski MP, Schatz M, Bulletins-Obstetrics ACoP. ACOG practice bulletin: clinical management guidelines for obstetriciangynecologists number 90, February 2008: asthma in pregnancy. *Obstet Gynecol.* 2008;111 (2 Pt 1):457–464.
- Vlastarakos PV, Manolopoulos L, Ferekidis E, et al. Treating common problems of the nose and throat in pregnancy: what is safe? *Eur Arch Otorhinolaryngol.* 2008;265:499–508.